Inovio To Start Global Late-Stage COVID-19 Vaccine Trial
The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's (NASDAQ: INO) global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-4800, DNA COVID-19 vaccine candidate.
Related Content: Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study.
Inovio plans to conduct the global Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co Ltd.
Phase 3 will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart.
The primary endpoint of the trial is virologically confirmed COVID-19.
Also Read: Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants.
Earlier this month, China signed off two clinical trials for heterologous boosting with INO-4800 through Advaccine as the trial sponsor.
Working with Sinovac Biotech Ltd (NASDAQ: SVA), Advaccine will evaluate the heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac.
Related content: Benzinga's Full FDA Calendar.
Price Action: INO shares are up 9.47% at $9.23 during the market session on the last check Thursday.
See more from Benzinga
Pfizer-BioNTech Ink COVID-19 Vaccine Manufacturing Pact For Latin America
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.